Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02379455
Other study ID # 222033/H10
Secondary ID
Status Completed
Phase N/A
First received February 27, 2015
Last updated January 24, 2018
Start date March 2015
Est. completion date September 22, 2017

Study information

Verified date January 2018
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Polypharmacy increases the risk of adverse drug effects, interactions and other drug-related problems, and several studies indicate that inappropriate drug use is a major reason for poor health and impaired function in the elderly. A majority of interventions for improvement of drug treatment in the elderly have been evaluated by the use of surrogate outcomes such as drug-related problems, number of prescribed drugs or prevalence of potentially inappropriate prescriptions - and it is so far unclear whether such interventions can result in clinical significant improvements. The primary objective of this trial is therefore to evaluate the effect upon patients, relatives and local health care service of a structured cooperation between a hospital-based geriatrician and family physicians on complex drug regimens in home-dwelling frail elderly patients.


Description:

This is a 24 weeks cluster randomized, single-blinded, controlled trial. Family physicians will be invited to participate in the project with patients from their lists, and can participate with 1-5 patients each. The investigators will carry out cluster randomization on physician level instead of individual randomization on patient level.

The investigators suppose that such a comprehensive clinical evaluation and drug review that they will test, is most relevant for patients with relatively pronounced polypharmacy. It has previously been shown that conventionally used limits for polypharmacy, e.g. five drugs used regularly, identifies many patients without particular complex health states and without drug related problems. The investigators will therefore limit this project to patients using seven regular drugs or more, in order to increase the likelihood that they may benefit from a drug review.

A major challenge when studying complex interventions is to describe the intervention with sufficient precision as to facilitate replication. Our main strategy for this will be to compensate for the necessary degree of pragmatism in the interventional approach with a detailed description of the interventions that were in fact carried out, in particular changes in the drug regimens of the individual patients.

The intervention will consist of three main parts:

1. Geriatric assessment: The patients will be seen by a physician trained in geriatric medicine. The physician will carry out a medical history and a physical examination, and relevant blood analyses and other supplementary test will be ordered if not already available. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. Published tools like the START (Screening Tool of Older Persons' Prescriptions) criteria, Screening Tool to Alert doctors to Right Treatment (STOPP) criteria and The Norwegian General Practice (NORGEP) criteria will be used.

2. Conference with common drug review: The main purpose of this conference is to combine the competence of the geriatrician and that of the family physician in a focused drug review. The two physicians will discuss the patient's drug list systematically. The geriatrician may suggest changes in the drug regimen, but the family physician retains the medical responsibility for the patient and is in charge of all ordinations and medication changes.

3. Clinical follow-up: Depending on medication changes that have been done, the two physicians will arrange the necessary follow-up within the project period.

The investigators will assess the outcomes at 16 and 24 weeks, counted from baseline, and will also assess baseline values for the outcomes in order to adjust for potential inequalities.


Recruitment information / eligibility

Status Completed
Enrollment 192
Est. completion date September 22, 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria:

- The patient must be on the list of one of the family physicians participating in the study

- Home dwelling (not permanently institutionalised)

- Medications administered by the home nursing service

- Polypharmacy defined as the use of at least seven different systemic medications taken regularly

- Informed consent by the patient or a close relative

Exclusion Criteria:

- Patient or relative denies inclusion

- The family physician does not want the particular patient to participate

- Moderate/severe dementia (Clinical Dementia Rating Scale score > 1) and contact with the closest proxy less than once every other week.

- The patient does not speak/understand Norwegian

- Expected to become permanently institutionalised within six months

- Life expectancy < six months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Comprehensive drug review
1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.

Locations

Country Name City State
Norway Dept. of Geriatric Medicine, Oslo University Hospital Oslo

Sponsors (3)

Lead Sponsor Collaborator
Oslo University Hospital The Research Council of Norway, University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Health-related quality of life as measured with 15D 16 weeks
Secondary Short Physical Performance Battery (SPPB) 16 weeks
Secondary Short Physical Performance Battery (SPPB) 24 weeks
Secondary Gait speed 16 weeks
Secondary Gait speed 24 weeks
Secondary Hand grip strength 16 weeks
Secondary Hand grip strength 24 weeks
Secondary Functional Independence Measure (FIM) 16 weeks
Secondary Functional Independence Measure (FIM) 24 weeks
Secondary Trail making test A and B 16 weeks
Secondary Trail making test A and B 24 weeks
Secondary Digit Span 16 weeks
Secondary Digit Span 24 weeks
Secondary Five Digits Test 16 weeks
Secondary Five Digits Test 24 weeks
Secondary Medication Appropriateness Index (MAI) 16 weeks
Secondary Medication Appropriateness Index (MAI) 24 weeks
Secondary Assessment of Underutilization (AOU) 16 weeks
Secondary Assessment of Underutilization (AOU) 24 weeks
Secondary Number of falls Recorded with the aid of diaries kept by patients/caregivers During the first 16 weeks after baseline
Secondary Number of falls Recorded with the aid of diaries kept by patients/caregivers During the first 24 weeks after baseline
Secondary Orthostatic blood pressure 16 weeks
Secondary Orthostatic blood pressure 24 weeks
Secondary Changes in body weight 16 weeks
Secondary Changes in body weight 24 weeks
Secondary Relative Stress Scale 16 weeks
Secondary Relative Stress Scale 24 weeks
Secondary Number of hospital admissions (with reasons) During the first 16 weeks from baseline
Secondary Number of hospital admissions (with reasons) During the first 24 weeks from baseline
Secondary Number of days in own home (in contrast to being in hospital or nursing home) During the first 16 weeks from baseline
Secondary Number of days in own home (in contrast to being in hospital or nursing home) During the first 24 weeks from baseline
Secondary Admission to permanent institutional care 16 weeks
Secondary Admission to permanent institutional care 24 weeks
Secondary Current use of home nursing service 16 weeks
Secondary Current use of home nursing service 24 weeks
Secondary Mortality 16 weeks
Secondary Mortality 24 weeks
Secondary Health-related quality of life as measured with 15D 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06020391 - Cooperation for Better Treatment of Polypharmacy in the Community N/A
Completed NCT02490345 - Gabapentin as Adjunctive Treatment for Postoperative Pain Control Phase 1
Completed NCT01931683 - Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA) Phase 4
Withdrawn NCT03938077 - A Community-University Approach to Preventing HIV N/A
Completed NCT02973724 - EC95 of Remifentanil for Preventing Cough N/A
Completed NCT01152970 - F.Y.I.: Flint Youth Injury Study N/A
Completed NCT03330782 - Remifentanil for Preventing Propofol Injection Pain in Elderly Patients Phase 4
Completed NCT01489683 - Intubating Conditions During Propofol-remifentanil Anesthesia With Topical Lidocaine N/A
Completed NCT03368456 - Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention N/A
Completed NCT01852539 - Dexmedetomidine for Laryngeal Mask Airway Insertion Phase 4
Completed NCT01963130 - Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study N/A
Recruiting NCT01496105 - Efficacy Study of Topical Application of Lidacaine Spray Prior to IUD Insertion Phase 4
Completed NCT02334046 - Remifentanil for Smooth Emergence in Elderly Patients Phase 4
Completed NCT00876941 - Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use Phase 3